If youre eligible you can call us at 855-582-2024, Monday through Friday, from 9 a.m
Conversely, we found little evidence that GLP-1RAs may cause or exacerbate cognitive impairment, which is of importance to patients who may need to take these medications for their currently licensed (and expanding) indications
Priority Review designation is possible given the magnitude of the trial results, which could shorten this timeline to 6 months
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
Pemvidutide is another dual agonist of GLP-1R and GCGR that is currently under clinical investigation
Whats the difference between Ozempic, Wegovy, Mounjaro, and Zepbound